Blood & Cancer

EHA25 highlights: EHA President John Gribben talks AML, myeloma, polycythemia vera, and COVID-19 What were the late-breaking and practice-changing presentations at EHA25 Virtual? John Gribben, MD, DSc, president of the European Hematology Association, highlighted some of them in this podcast. Dr. Gribben and host David H. Henry, MD, discussed presentations on acute myeloid leukemia (AML), multiple myeloma, polycythemia vera (PV), and COVID-19. Videos of these and other presentations will be available on the EHA25 website until Oct. 15.  Randomized, double-blind, placebo-controlled study of venetoclax with azacitidine vs. azacitidine in treatment-naïve patients with acute myeloid leukemia ineligible for intensive therapy—VIALE-A: Adding venetoclax to azacitidine improved survival, response, and transfusion independence in older patients with treatment-naïve AML.  Older AML patients have seen “very little progress” in outcomes for decades, but advances such as these are “really moving the field,” Dr. Gribben